

(51) International Patent Classification:

C07C 237/22 (2006.01) C07C 311/19 (2006.01)

C07C 311/06 (2006.01) C07D 207/16 (2006.01)

C07K 5/06 (2006.01)

(21) International Application Number:

PCT/GB2012/051588

(22) International Filing Date:

6 July 2012 (06.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1111682.9 7 July 2011 (07.07.2011) GB

61/505,305 7 July 2011 (07.07.2011) US

(71) Applicant (for all designated States except US): **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Building 227, Tetricus Science park, Salisbury, Wiltshire SP4 0JQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EVANS, David Michael** [GB/GB]; c/o KalVista Pharmaceuticals, Building 227, Tetricus Science Park, Salisbury SP4 0JQ (GB). **DAVIE, Rebecca Louise** [GB/GB]; c/o KalVista Pharmaceuticals, Building 227, Tetricus Science Park, Salisbury SP4 0JQ (GB). **EDWARDS, Hannah Joy** [GB/GB]; c/o KalVista Pharmaceuticals, Building 227, Tetricus Science Park, Salisbury SP4 0JQ (GB). **ROOKER, David Philip** [GB/GB]; c/o KalVista Pharmaceuticals, Building 227, Tetricus Science Park, Salisbury SP4 0JQ (GB).

(74) Agents: **HALLYBONE, Huw George** et al.; Carpmaels & Ransford, One Southampton Row, Holborn, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN



(57) Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R¹ to R⁹ are as defined herein.